Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

Cote d’Ivoire launches Ebola vaccination of first responders and health workers

Cote d’Ivoire has launched Ebola vaccination of high-risk populations, including health workers and first responders in Abidjan, where an Ebola outbreak was declared on 14 August.

17 Aug 2021

Data reinforces SAB-185’s potential to neutralize SARS-CoV-2 variants

A study, available on the pre-print server bioRxiv*, evaluated the neutralizing capacity of a fully human polyclonal antibody (SAB-185) against the Delta, Kappa, and Lambda variants using a lentiviral-based pseudovirus assay.

17 Aug 2021

Camelid nanobody anti-SARS-CoV-2 drug candidates

In a research paper recently published in the journal eLife, researchers from several US institutions have developed a nanobody-based candidate drug that effectively prevents and suppresses severe SARS-CoV-2 infection in animals.

12 Aug 2021

Small NIH clinical trial shows that new monoclonal antibody can prevent malaria

One dose of a new monoclonal antibody discovered and developed at the National Institutes of Health safely prevented malaria for up to nine months in people who were exposed to the malaria parasite.

11 Aug 2021

Study defines SARS-CoV-2 antibodies associated with neutralization and effector functions

A new study explores the polyclonal antibody response to SARS-CoV-2 in greater detail.

10 Aug 2021

New insight into impact of SARS-CoV-2 mutations on receptor binding

A recent study by Canadian researchers, currently available on the bioRxiv* preprint server, contributes to the growing body of literature on emerging variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by appraising the impact of single mutations on their overall antigenicity and binding affinity for the angiotensin-converting enzyme 2 (ACE2) receptor.

9 Aug 2021

Aducanumab approval for Alzheimer's may provide a proof of concept that can be rapidly improved upon

The recent US Food and Drug Administration (FDA) approval of aducanumab – which has the potential to treat Alzheimer's disease – may provide a proof of concept that can be rapidly improved upon, writes Dennis Selkoe in this Perspective.

6 Aug 2021

Combination therapy improves outcomes for relapsed chronic lymphocytic leukemia

Shuo Ma, MD, '00 PhD, associate professor of Medicine in the Division of Hematology and Oncology, was co-first author of the clinical trial published in Blood.

5 Aug 2021

Monoclonal antibody could inform development of pan-coronavirus vaccines

Researchers in the United States have demonstrated the potential of a monoclonal antibody to inform the design of pan-coronavirus vaccines that could prevent the outbreak of future pandemics such as coronavirus disease 2019 (COVID-19).

4 Aug 2021

SARS-CoV-2 Q493R protein mutation shows resistance to monoclonal antibodies

The Centers for Disease Control and Prevention (CDC) issued a letter detailing a case of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in an immunocompromised patient who did not respond well to monoclonal antibody treatment. The resistance to treatment stemmed from an escape mutation on the spike protein known as Q4923R.

2 Aug 2021

Spike-containing virus-like particles induce robust sterilizing immunity against SARS-CoV-2 in macaques

A team of international scientists has recently developed virus-like particles (VLPs) by coating liposomes with the synthetic spike glycoprotein of SARS-CoV-2.

28 Jul 2021

Impaired immune response to SARS-CoV-2 mRNA vaccination in immunocompromised patients

A new study describes how immunocompromised vaccine recipients may not always respond as expected to the COVID-19 vaccine.

27 Jul 2021

Monoclonal antibody CT-P59 demonstrates potent antiviral efficacy against SARS-CoV-2 delta variant

A Korean study has recently demonstrated antiviral potency of monoclonal antibody CT-P59 against the delta variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The experiments conducted in animals infected with the delta variant have shown that CT-P59 is able to reduce symptom intensity and viral replication in the respiratory tract. The study is currently available on the bioRxiv* preprint server.

27 Jul 2021

Synergistic multi-antibody cocktail protects against SARS-CoV-2 in animal model

Researchers in Canada have reported the discovery of a multi-antibody cocktail that synergistically protected against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in an animal model of acute infection.

22 Jul 2021

Clinical trial to test personalized treatment for severe asthma caused by a specific mutation

Under a $10 million grant, a randomized, placebo-controlled clinical trial led by Boston Children's Hospital will test a personalized treatment for a form of severe asthma to which Black and Latinx children and adults are especially vulnerable.

21 Jul 2021

Combination of investigational therapeutic and chemotherapy shows promise for AML treatment

The investigational therapeutic ficlatuzumab in combination with chemotherapy showed signs of clinical efficacy in patients with relapsed/refractory acute myeloid leukemia.

16 Jul 2021

Researchers examine efficacy of CT-P59 monoclonal antibody against SARS-CoV-2 Brazil variant

The therapeutic monoclonal antibody CT-P59 binds to the RBD of SARS-CoV-2, the site of these three major mutations, which may therefore reduce the potency of this antibody against the P.1 lineage. In a new study, the neutralizing potency of this monoclonal antibody towards both wildtype and P.1 SARS-CoV-2 is investigated. The researchers found that the ability to bind with the virus is impeded by the mutations, resulting in reduced potency in vitro.

14 Jul 2021

Monoclonal Antibody News and Research

Further Reading

Cote d’Ivoire launches Ebola vaccination of first responders and health workers

Data reinforces SAB-185’s potential to neutralize SARS-CoV-2 variants

Camelid nanobody anti-SARS-CoV-2 drug candidates

Small NIH clinical trial shows that new monoclonal antibody can prevent malaria

Study defines SARS-CoV-2 antibodies associated with neutralization and effector functions

New insight into impact of SARS-CoV-2 mutations on receptor binding

Aducanumab approval for Alzheimer's may provide a proof of concept that can be rapidly improved upon

Combination therapy improves outcomes for relapsed chronic lymphocytic leukemia

Monoclonal antibody could inform development of pan-coronavirus vaccines

SARS-CoV-2 Q493R protein mutation shows resistance to monoclonal antibodies

Spike-containing virus-like particles induce robust sterilizing immunity against SARS-CoV-2 in macaques

Impaired immune response to SARS-CoV-2 mRNA vaccination in immunocompromised patients

Monoclonal antibody CT-P59 demonstrates potent antiviral efficacy against SARS-CoV-2 delta variant

Synergistic multi-antibody cocktail protects against SARS-CoV-2 in animal model

Clinical trial to test personalized treatment for severe asthma caused by a specific mutation

Combination of investigational therapeutic and chemotherapy shows promise for AML treatment

Researchers examine efficacy of CT-P59 monoclonal antibody against SARS-CoV-2 Brazil variant

Neutralizing aptamers block SARS-CoV-2 infection in vitro

Novel monoclonal antibody could pave way for future COVID-19 treatments and vaccines

Kids misusing soft drinks to corrupt SARS-CoV-2 tests

Antibodies eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®